Revolution Medicines (RVMD) Corporate presentation summary

Mission and strategic focus

• Aims to revolutionize treatment for RAS-addicted cancers with innovative targeted medicines, focusing on pancreatic, non-small cell lung, and colorectal cancers.

• Over 2,500 patients have been treated with RAS(ON) inhibitors; four clinical-stage drugs are in development, with eight Phase 3 trials active or planned for 2026.

• Proprietary tri-complex discovery platform targets the oncogenic state of RAS, driving continuous innovation.

Clinical pipeline and development

• Lead compounds include daraxonrasib (multi-selective), zoldonrasib (G12D), elironrasib (G12C), and RMC-5127 (G12V), with additional preclinical assets targeting other RAS mutations.

• Multiple registrational trials are underway or planned across pancreatic, NSCLC, and colorectal cancers, including monotherapy and combination regimens.

• Daraxonrasib and zoldonrasib are being evaluated in both first- and second-line metastatic pancreatic cancer, with completed and ongoing enrollments.

Key clinical results

• Daraxonrasib shows compelling activity in 2L metastatic PDAC: ORR 35%, DCR 92%, median PFS 8.5 months, median OS 13.1 months.

• In 1L PDAC, daraxonrasib monotherapy achieved ORR 47%, DCR 89%, and was generally well tolerated.

• Combination of daraxonrasib + GnP in 1L PDAC yielded ORR 55%, DCR 90%, with acceptable safety and dose intensity.

• Zoldonrasib monotherapy in previously treated KRAS G12D PDAC showed ORR 30%, DCR 80%.

• In NSCLC, daraxonrasib demonstrated median PFS 9.8 months and OS 17.7 months in 2L/3L RAS G12X patients.

• Elironrasib monotherapy in previously treated RAS G12C NSCLC achieved ORR 56%, DCR 94%, median PFS 9.9 months.